The death of a participant in a clinical trial of an antibody treatment for Alzheimer’s disease, which is now under consideration by the US Food and Drug Administration, may be linked to the experimental drug, a new report shows.
Alzheimer’s disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common cause of dementia in older adults and is characterized by the gradual loss of cognitive function and the accumulation of abnormal protein deposits in the brain.